EP2762132A1 — Controlled Release 25-Hydroxyvitamin D
Assigned to Opko Ireland Global Holdings Ltd · Expires 2014-08-06 · 12y expired
What this patent protects
The invention provides 25-hydroxyvitamin D for use in the treatment of hyperparathyroidism by controlled release. The 25-hydroxyvitamin D is administered by intravenous delivery, especially in dosage amounts of from 1 to 100 µg per day. The 25-hydroxyvitamin D may be (a) 25-hydro…
USPTO Abstract
The invention provides 25-hydroxyvitamin D for use in the treatment of hyperparathyroidism by controlled release. The 25-hydroxyvitamin D is administered by intravenous delivery, especially in dosage amounts of from 1 to 100 µg per day. The 25-hydroxyvitamin D may be (a) 25-hydroxyvitamin D2 or (b) 25-hydroxyvitamin D3 or (c) a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.